American Association for Cancer Research

SHERPA: Unknown

People

  1. Solit
    Solit
  2. Ladanyi
    Ladanyi
  3. Rosen
    Rosen
  4. Hudis
    Hudis
  5. Scher
    Scher
  6. Berger
    Berger
  7. Baselga
    Baselga
  8. Reis-Filho
    Reis-Filho
  9. Cordon-Cardo
    Cordon-Cardo
  10. Schultz
    Schultz

Groups

  1. Department of Medicine (2074)
  2. Solid Tumor Oncology Division (1737)
  3. GSK Faculty (1623)
  4. Sloan Kettering Institute Faculty (794)
  5. Sloan Kettering Institute Postdocs (766)
  6. Department of Pathology and Laboratory Medicine (715)
  7. Human Oncology and Pathogenesis Program (677)
  8. Surgery (639)
  9. Breast Medicine Service (605)
  10. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (570)
Search Within
Formats
  1. Meeting Abstract (1996)
  2. Journal Article (1966)
  3. Editorial (41)
  4. Review (22)
  5. Conference Paper (14)
  6. Correspondence (4)
  7. Miscellaneous (4)
  8. Guidelines (1)
Groups
  1. Department of Medicine (2074)
  2. Solid Tumor Oncology Division (1737)
  3. GSK Faculty (1623)
  4. Sloan Kettering Institute Faculty (794)
  5. Sloan Kettering Institute Postdocs (766)
  6. Department of Pathology and Laboratory Medicine (715)

More Groups

People
  1. David Solit (174)
  2. Marc Ladanyi (157)
  3. Neal Rosen (141)
  4. Clifford Hudis (140)
  5. Howard Scher (139)
  6. Jose Baselga (138)

More People

Years
  1. 2025 (6)
  2. 2024 (55)
  3. 2023 (63)
  4. 2022 (261)
  5. 2021 (233)
  6. 2020 (271)

More Years

Publications
  1. Cancer Research (2685)
  2. Clinical Cancer Research (1363)

Results (4048)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Phase I trial of sequential paclitaxel and cisplatin in combination with the cyclin dependent kinase inhibitor flavopiridol (flavo) in patients with advanced solid tumors
    Meeting Abstract

    Schwartz, G. K.; Kaubisch, A.; Saltz, L.; Ilson, D.; O'Reilly, E.; Barazzuol, J.; Endres, S.; Stoltz, M.; Tong, W.; Kelsen, D. P.; more...
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Selective inhibition of cyclooxygenase-2 enhances mitomycin-C-induced apoptosis
    Meeting Abstract

    Hsueh, C. T.; Kelsen, D. P.; Schwartz, G. K.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • The use of the prostate xenograft CWR22 and its androgen independent sublines in the preclinical development of herceptin
    Meeting Abstract

    Higgins, B.; Fox, W. D.; Maiese, K.; Fazzari, M.; Scher, H. I.; Agus, D. B.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by co-administration of ZD1839 (Iressa™), an inhibitor of EGF receptor tyrosine kinase
    Meeting Abstract

    Sirotnak, F. M.; Miller, V. A.; Scher, H. I.; Kris, M. G.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Phase I study of oral ZD1839 (Iressa™), a novel inhibitor of epidermal growth factor receptor tyrosine kinase (EGFR-TK): Evidence of good tolerability and activity
    Meeting Abstract

    Kris, M.; Ranson, M.; Ferry, D.; Hammond, L.; Averbuch, S.; Ochs, J.; Rowinsky, E.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • The antitumor agent Ecteinascidin 743 (ET743), inhibits transcriptional activation of the MDR1 Gene by multiple inducers
    Meeting Abstract

    Jin, S. K.; Hu, Z.; Scotto, K. W.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Potent antitumor activity of FT-743 against human soft tissue sarcoma cell lines
    Meeting Abstract

    Li, W.; Jhanwar, S.; Elisseyeff, Y.; Bertino, J. R.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Co-administration of probenecid, an inhibitor of a cMOAT/MRP-like plasma membrane ATPase, greatly enhanced the efficacy of a new 10-deazaaminopterin against human solid tumors in vivo
    Meeting Abstract

    Sirotnak, F. M.; Bornmann, W. G. B.; Miller, V. A.; Scher, H. I.; Kris, M. G.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Human pharmacokinetics of T138067, a novel antimicrotubule agent, given as a 3-hour infusion once every 21 to 28 days
    Meeting Abstract

    Berg, W.; Vongphrachanh, P.; Walling, J.; Wright, M.; Ye, Q.; Peterson, K.; Motzer, R.; Thoolen, M.; Timmermans, P.; Soignet, S.; more...
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save
  • Hyperthermia could inhibit the expression of multidrug resistance gene (MDR1) and GSTpi gene in bladder carcinoma cells and increase the intracellular accumulation of Daunorubicin
    Meeting Abstract

    Song, Y. S.; Jia, W. Y.; Lee, W. L.; Liu, H. Y.; Wang, L. M.; Yang, Y.
    Clinical Cancer Research (1999)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: